- TOTAL30 contact lenses to be showcased at the conference
through in-booth lens try-on, an exclusive launch event for eye
care professionals, scientific data presentations and more
- Numerous clinical presentations to affirm the efficacy of
Alcon’s portfolio of contact lenses that contain proprietary
permanent water surface technologies
- “Coming soon” contact lens and dry eye portfolio expansions to
be previewed, including DAILIES TOTAL1 for Astigmatism and
more
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people see brilliantly, will showcase leading
innovations and clinical research findings at the American Academy
of Optometry Annual Meeting (#Academy21) in Boston, Massachusetts,
from November 3-6, 2021. The meeting will mark the official launch
of TOTAL30®, the first-and-only monthly replacement Water Gradient
contact lens that feels like nothing even on day 30,1 to the
professional eye care community. Alcon’s engaging on-site program
will feature events and more than a dozen clinical presentations
around their most important eye care products, including the
portfolio of permanent water surface technology contact lenses, dry
eye and ocular health drops, and forthcoming innovations.
“Year after year, Alcon has delivered significant innovations
across our Vision Care portfolio that help eye care professionals
(ECPs) connect unmet patient and practice needs with
industry-transforming products,” said Sean Clark, General Manager,
U.S. Vision Care, Alcon. “We are thrilled to officially introduce
TOTAL30 contact lenses to the optometry community at this year’s
Academy meeting as an important option for their reusable lens
patients seeking a more comfortable wearing experience. Our program
is jam-packed with events centered around TOTAL30 and other
important innovations that demonstrate our commitment to helping
people see brilliantly.”
TOTAL30 Contact Lenses to Officially Debut with
Scientific Presentations, Immersive ECP Evening Event and Lens
Try-On In August, Alcon launched TOTAL30 monthly replacement
contact lenses, which are clinically shown to feel like nothing,
even at day 30.1 The lens science was born from the Water Gradient
technology of DAILIES TOTAL1®. The following events will give
meeting attendees hands-on experiences with the design and science
of the lens throughout the meeting:
- The Science of Nothing Luncheon: Drs. Pamela Lowe and Erich
Bauman. 12-1 p.m. ET. The presentation will take place at The
Westin Boston Seaport (425 Summer St, Boston, MA 02210) in Grand
Ballroom B.
- The Joy of Nothing Launch Experience: Join us for an exciting,
immersive launch event that will showcase the art and science
behind TOTAL30's Water Gradient and CELLIGENT® technologies. Food
and beverages will be provided. November 4, 2021, 6:30-8:30 p.m. ET
at The Westin Boston Seaport in Grand Ballroom A. Register for the
event here or visit Alcon booth #813.
- TOTAL30 Lens Try-On: Stop by and experience first-hand why
TOTAL30 is poised to be a game-changer in the reusable lens
category and why it feels like nothing, even at day 30. Visit Alcon
booth #813 during exhibit hall hours.
Additionally, there will be several data presentations taking
place on Thursday, November 4, 2021, on the efficacy and clinical
performance of TOTAL30, including:
- Paper Presentation: Antimicrobial Efficacy of Contact Lens Care
Products in the Presence of Lehfilcon A Contact Lenses. Presented
by Dr. Manal M. Gabriel, 10:15-10:30 a.m. ET.
- Poster Presentation: Consistent Comfort, Vision and Handling
Performance of a New Monthly Replacement Spherical Contact Lens
Over 3 Months of Daily Wear. Presented by Dr. Holly Lorentz,
4:30-6:30 p.m. ET.
- Poster Presentation: Clinical Performance Evaluation of
Lehfilcon A Monthly Replacement Silicone Hydrogel Toric Contact
Lenses. Presented by Dr. Stephen Montaquila, 4:30-6:30 p.m.
ET.
- Poster Presentation: Clinical Performance of Two Monthly
Replacement Spherical Contact Lenses. Presented by Dr. Gina Wesley,
4:30-6:30 p.m. ET.
Clinical and Survey Data Affirms Efficacy of PRECISION1 Water
Surface Technology Several clinical studies will be presented
on November 4, 2021, highlighting PRECISION1® and PRECISION1 for
Astigmatism, Alcon’s one-day contact lenses, made with permanent
water surface technology that keeps moisture on the lens surface
for patient comfort.2 Data highlights include:
- Poster Presentation: Assessment of Evening Comfort and Vision
with Water Surface Silicone Hydrogel Daily Disposable Lenses.
Presented by Dr. Jennifer S. Fogt, 4:30-6:30 p.m. ET.
- Poster Presentation: Practitioners Have High Satisfaction with
SMARTSURFACE® TECHNOLOGY Daily Disposable Contact Lenses. Presented
by Dr. Timothy Grant, 4:30-6:30 p.m. ET.
- Poster Presentation: Contact Lens Wearers Have High
Satisfaction with SMARTSURFACE® TECHNOLOGY Daily Disposable Contact
Lenses. Presented by Dr. Timothy Grant, 4:30-6:30 p.m. ET.
- Poster Presentation: Subjective Performance of Verofilcon A
Daily Disposable Soft Contact Lens After 16 Hours of Wear.
Presented by Dr. Colton M. Heinrich, 4:30-6:30 p.m. ET.
- Poster Presentation: Assessment of U.S. Eye Care Professional
and Consumer Satisfaction with Verofilcon A Daily Disposable
Silicone Hydrogel Contact Lenses for Astigmatism. Presented by Dr.
Carla Mack, 4:30-6:30 p.m. ET.
- Poster Presentation: Evaluation of Wear Experience with Water
Surface Lenses in Current Wearers of Silicone Hydrogel Planned
Replacement Lenses. Presented by Dr. Ryan Rutschilling, 4:30-6:30
p.m. ET.
- Poster Presentation: Survey of Patient and ECP Satisfaction
with a New Daily Disposable Toric Contact Lens. Presented by Dr.
Inma Perez-Gomez, 4:30-6:30 p.m. ET.
New Clinical Findings Affirm Efficacy of Products in Alcon’s
Dry Eye and Ocular Health Portfolio Alcon’s dry eye and ocular
health portfolio features over-the-counter solutions and in-office
devices, such as Systane® iLux®, Pataday® Once Daily Relief Extra
Strength, and a variety of other brands, which support ocular
surface health, dry eye, eye allergy itch symptom relief and more.
Data highlights being presented at #Academy21 include:
- November 4, 2021
- Poster Presentation: Thermal Pulsation System in the Treatment
of Meibomian Gland Dysfunction: A 12-Month, Randomized, Prospective
Comparative Trial. Presented by Dr. David Kading, 4:30-6:30 p.m.
ET.
- Poster Presentation: Understanding Comfort Differences Between
Pataday Once Daily Relief Extra Strength & Visine^ Allergy Eye
Relief Multi-Action Drops. Presented by Dr. Christopher Lievens,
4:30-6:30 p.m. ET.
- November 5, 2021
- Poster Presentation: Understanding Ocular Comfort Differences
Between Pataday Once Daily Relief Extra Strength and Alaway^.
Presented by Dr. Amy Logan, 10 a.m.-12 p.m. ET.
Portfolio Expansions Will Deliver Industry Innovations for
Unmet Patient, Practice Needs In addition to the highlighted
products and science noted above, Alcon is expanding its portfolio
in 2022 with exciting new products, including:
- DAILIES TOTAL1 for Astigmatism, the much-anticipated toric lens
born from the trusted Water Gradient lens technology of DAILIES
TOTAL1 sphere and multifocal lenses.
- Systane® Complete Multi-Dose Preservative Free, an all-in-one
dry eye drop that delivers eight hours of dry eye symptom relief3
in a preservative-free formulation.
- An upgraded dry eye device system that treats Meibomian Gland
Dysfunction.
In addition, Alcon recently acquired exclusive U.S.
commercialization rights to Simbrinza® (brinzolamide/brimonidine
tartrate ophthalmic suspension) 1%/0.2%, a fixed combination
indicated in the reduction of elevated intraocular pressure (IOP)
in patients with open-angle glaucoma or ocular hypertension.
Visit Alcon booth #813 for important information on Alcon’s
innovative products featured in this release.
Cautionary Note Regarding
Forward-Looking Statements This press release contains
“forward-looking statements” within the meaning of the safe harbor
provisions of the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by
words such as: “anticipate,” “intend,” “commitment,” “look
forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,”
“estimate,” “expect,” “strategy,” “future,” “likely,” “may,”
“should,” “will” and similar references to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations, and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. In particular, our
expectations could be affected by uncertainties regarding the
success of our separation and spin-off from Novartis. Should one or
more of these uncertainties or risks materialize, or should
underlying assumptions prove incorrect, actual results may vary
materially from those anticipated. Therefore, you should not rely
on any of these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
About Alcon Alcon helps
people see brilliantly. As the global leader in eye care with a
heritage spanning more than seven decades, we offer the broadest
portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of more than
260 million people in over 140 countries each year living with
conditions like cataracts, glaucoma, retinal diseases, and
refractive errors. Our more than 23,000 associates are enhancing
the quality of life through innovative products, partnerships with
eye care professionals and programs that advance access to quality
eye care. Learn more at www.alcon.com.
^ Trademarks are the property of their respective owners.
References
- In a clinical study wherein patients (n=66) used CLEAR CARE®
solution for nightly cleaning, disinfecting, and storing; Alcon
data on file, 2021.
- Cummings S, Giedd B, Pearson C. Clinical performance of a new
daily disposable spherical contact lens. Optom Vis Sci. 2019;96: E
Abstract 195375.
- Silverstein S, Yeu E, Tauber J, et al. Symptom Relief Following
a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion
in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial.
Clin Ophthalmol. 2020; 14:3167-3177.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211101005854/en/
Media Relations Kimberly
Wise + 1 817 615 5092 (direct) + 1 817 525 3409 (mobile)
kimberly.wise@alcon.com
Investor Relations Allen
Trang + 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From May 2024 to Jun 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Jun 2023 to Jun 2024